Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04023266
Other study ID # Pro00087545
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 20, 2019
Est. completion date January 1, 2022

Study information

Verified date July 2022
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PANACEA trial is an investigator-initiated prospective, single-center, two-arm, non-blinded pilot randomized controlled trial of high-dose IV N-Acetylcysteine therapy used as an adjunct to pharmaco-invasive reperfusion in patients presenting early after a large STEMI.


Description:

Patients presenting with ST-segment elevation myocardial infarction within 3 hours of symptom onset and satisfying all of the inclusion criteria after informed consent would be randomly allocated to either intravenous N-Acetylcysteine or standard treatment using a 1:1 allocation ratio. Those randomized to IV N-Acetylcysteine would be administered a bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours. The infusion is continued during the primary percutaneous coronary intervention. Patients would be followed up for a minimum of 90 days. The primary clinical endpoint will be myocardial infarct size measured by late gadolinium enhancement CMR imaging at 3-5 days from first medical contact. Primary feasibility outcome will be the rate of recruitment, the number of patients undergoing cardiac MRI within the stipulated time frame, and completeness of the study data collection.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date January 1, 2022
Est. primary completion date November 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients presenting with STEMI within 3 hours of symptom onset and satisfying all of the following criteria: 1. Patient age = 18 years 2. Have received thrombolysis, with intend to pursue a pharmaco-invasive reperfusion strategy. Onset of chest pain to reperfusion time of < 3hrs. 3. STEMI involving anterior and/or inferior wall 4. An absence of baseline Q-waves on the initial ECG: The presence of Q waves defined at baseline using the Selvester QRS screening criteria 5. Have a high-risk STEMI ECG defined as: - =2mm ST-segment elevation in 2 anterior or lateral leads; or - =2 mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of =4 mm Exclusion Criteria: 1. Previous myocardial infarction 2. Known to have moderate to severe LV systolic dysfunction (LV EF< 45%) 3. Known allergy to thrombolytic therapy or NAC 4. Presence of left bundle branch block 5. Cardiogenic shock (defined as systolic blood pressure of < 90mm Hg, for at least 30 minutes, not responsive to fluid resuscitation) 6. Permanent pacemaker or cardioverter defibrillator implanted previously 7. Patients with contra-indications to thrombolytic therapy 8. Patients with loss of consciousness or confusion 9. Patients with known chronic kidney disease (GFR < 30ml/min/m2) or on dialysis 10. Current pregnancy 11. Planned therapy with primary PCI

Study Design


Related Conditions & MeSH terms

  • ST Elevation Myocardial Infarction
  • STEMI

Intervention

Drug:
Intravenous N-Acetylcysteine
Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.

Locations

Country Name City State
Canada University of Alberta Hospital Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial infarct size The primary clinical endpoint will be myocardial infarct size measured by late gadolinium enhancement CMR imaging at 3-5 days from first medical contact. 3-5 days after first medical contact
Primary Feasibility outcomes Primary feasibility outcomes would include the rate of recruitment, the number of patients undergoing cardiac MRI within the stipulated time frame, and completeness of the study data collection. Assessed at the end of the study
Secondary Myocardial salvage Myocardial salvage as measured by T2-weighted short tau inversion recovery on CMR assessed at 3-5 days after infarction 3-5 days after infarction
Secondary Left ventricular ejection fraction Left ventricular ejection fraction on CMR at 3-5 days 3-5 days after infarction
Secondary ST-segment elevation resolution ST-segment elevation resolution at 90 minutes after thrombolysis as assessed by the worst lead on electrocardiogram (ECG core lab). 90-minutes after thrombolysis
Secondary TIMI frame count in infarct related artery TIMI frame count on baseline coronary angiogram in the infarct-related artery During index coronary angiogram which will be performed within 24 hours of admission
Secondary Creatine kinase MB area under the curve Creatine kinase MB area under the curve through 24 hours 24 hours after admission
Secondary Von Willebrand factor fragmentation The proportion of Von Willebrand factor multimers in the low, intermediate and high molecular weight form at the time of angiography At the time of angiography, assessed up to 7 days from admission
Secondary Bleeding Bleeding research consortium type II, III and V bleeding; safety outcome From time of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 90 days
Secondary Allergic reactions Allergic reactions including hypotension (SBP< 90 mm Hg or a fall in BP >30 mm Hg below baseline), urticaria, flushing, wheezing and/or angioedema From time of randomization, upto 48 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A
Completed NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Phase 2/Phase 3
Completed NCT01625104 - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI N/A
Completed NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation NCT03328156 - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction N/A
Completed NCT04017169 - No Reflow Phenomenon Incidence and Predictors
Completed NCT03470441 - A Study of Acute Myocardial Infarction Using FDY-5301 Phase 2
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01197742 - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction N/A
Terminated NCT03439150 - Resistance STEMI Study N/A
Recruiting NCT03998319 - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. Phase 3
Not yet recruiting NCT05974930 - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting NCT03102723 - Platelet Inhibition to Target Reperfusion Injury Phase 2
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Not yet recruiting NCT04912167 - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction Phase 3
Completed NCT02942550 - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients Phase 4
Recruiting NCT02604394 - Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden N/A